These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
171 related items for PubMed ID: 12745131
1. Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis. Weaver A, Alderman M, Sperling R. Am J Cardiol; 2003 May 15; 91(10):1291-2. PubMed ID: 12745131 [No Abstract] [Full Text] [Related]
6. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. Wolfe F, Zhao S, Pettitt D. J Rheumatol; 2004 Jun 15; 31(6):1143-51. PubMed ID: 15170928 [Abstract] [Full Text] [Related]
7. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. Arch Intern Med; 2005 Jan 24; 165(2):161-8. PubMed ID: 15668361 [Abstract] [Full Text] [Related]
14. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA. Lancet; 2004 May 29; 363(9423):1751-6. PubMed ID: 15172772 [Abstract] [Full Text] [Related]
15. Celecoxib, rofecoxib, and acute temporary visual impairment. Coulter DM, Clark DW, Savage RL. BMJ; 2003 Nov 22; 327(7425):1214-5. PubMed ID: 14630760 [No Abstract] [Full Text] [Related]
16. Cardiovascular and renal effects of COX-2-specific inhibitors: recent insights and evolving clinical implications. Epstein M. Am J Ther; 2001 Nov 22; 8(2):81-3. PubMed ID: 11304661 [No Abstract] [Full Text] [Related]
17. Cardiovascular events and COX-2 inhibitors. Fleming M. JAMA; 2001 Dec 12; 286(22):2808; author reply 2811-2. PubMed ID: 11735742 [No Abstract] [Full Text] [Related]
19. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. Hudson M, Richard H, Pilote L. BMJ; 2005 Jun 11; 330(7504):1370. PubMed ID: 15947399 [Abstract] [Full Text] [Related]
20. Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs. Budenholzer BR. BMJ; 2002 Jul 20; 325(7356):161; author reply 161. PubMed ID: 12130617 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]